血清可溶性Fas评判浅表性膀胱癌复发的意义-东南大学学报医学版

血清可溶性Fas评判浅表性膀胱癌复发的意义

单位：1. 南通大学附属东台医院泌尿外科, 江苏盐城 224200;
2. 国家安监总局煤炭总医院泌尿外科, 北京 100028

分类号：R737.14

出版年·卷·期（页码）：2015·34·第二期（231-234）

摘要：

目的:探讨血清可溶性Fas(sFas)与浅表性膀胱癌复发之间的关系.方法:将我院2006年1月至2009年12月69例术后病理确诊为浅表性膀胱癌患者作为实验组,随机选取40名健康者作为对照组,两组均空腹抽取静脉血,用双抗体夹心酶联免疫吸附法(ELISA)进行血清sFas水平检测并对结果进行比较;根据3年内复发情况,将实验组膀胱癌患者分为复发组与无复发组,比较两组血清sFas水平.结果:实验组复发18例,进展为肌肉浸润性膀胱癌(MIBC)13例.实验组血清sFas水平为(0.15±0.13) ng·ml^-1,对照组为(0.07±0.01) ng·ml^-1,两组差异具有统计学意义(P <0.05).复发组血清sFas水平为(0.16±0.08) ng·ml^-1,无复发组为(0.09±0.04) ng·ml^-1,两组差异具有统计学意义(P <0.05);进展为MIBC者血清sFas水平为(0.15±0.07) ng·ml^-1,未进展为MIBC者为(0.14±0.03) ng·ml^-1,两组差异无统计学意义(P >0.05).采用多元线性回归模型校正各因素后得出,膀胱灌注及血清sFas值是预测膀胱癌复发的独立因素;而膀胱癌肿瘤直径、G3分级及膀胱灌注是预测膀胱癌进展为MIBC的独立因素.结论:血清sFas可以作为预测浅表性膀胱癌复发的标志物,浅表性膀胱癌患者术前血清sFas水平可反映膀胱癌患者复发情况.

Objective: To explore the relationship between the serum soluble Fas(sFas) and recurrence of non-muscle invasive bladder cancer. Methods: 69 patients with non-muscle invasive bladder cancer diagnosised by postoperative pathology were choosed as experimental group in our hospital from January 2006 to December 2006, and 40 healthy patients were randomly selected as control group. Double antibody sandwich enzyme-linked immunosorbent (ELISA) was used to detect the serum level of sFas. According to the recurrent in three years, the experimental group was divided into two group with bladder cancer recurrence and non-recurrence, their serum sFas level was compared. Results: 18 cases grow back in this study, 13 cases progress of MIBC. The values of serum sFas was(0.15±0.13) ng·ml^-1 in experimental group and(0.07±0.01) ng·ml^-1 in control group, the difference was significant(P <0.05).Furthermore, the value of serum sFas in recurrence group was higher than that of the recurrence-free group(P <0.05), and the value of serum sFas in MIBC group was slightly higher than that of the non-MIBC group(P >0.05). By multiple linear regression model, bladder perfusion and serum sFas values were independent factors predicting recurrence of bladder cancer. Bladder tumor diameter, grade of G3 and bladder perfusion were predictors of progression to MIBC. Conclusion:Serum sFas is associated with recurrence of superficial bladder cancer, and preoperative serum sFas level of superficial bladder cancer patients can reflect the recurrence.

参考文献：

[1] KIEMENEY L A,WITJES J A,VERBEEK A L,et al.The clinical epidemiology of superficial bladder cancer.Dutch South-East Cooperative Urological group[J].British Journal of Cancer,1993,67(4):806-812.
[2] SYLVESTER R J,van der MEIJDEN A P,OOSTERLINCK W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49(3):466-477; discussion 475-457.
[3] HWANG E C,PARK S H,JUNG S I,et al.Usefulness of liquid-based preparation in urine cytology[J].Int J Urol,2007,14(7):626-629.
[4] MIZUTANI Y,YOSHIDA O,BONAVIDA B.Prognostic significance of soluble Fas in the serum of patients with bladder cancer[J].J Urol,1998,160(2):571-576.
[5] SAUTER G,ALGABA F,AMIN M,et al.Tumour of urinary system:non-invasive urothelial neoplasia[M]//EBLE J N,SAUTER G,EPSTEIN J I,SESTERHENN,eds.WHO Classification of tumour of urinary system and male genital organs.Lyon:IARCC Press,2004.
[6] SOBIN D H,WITTEKING C H.TNM Classification of Malignant Tumours[M].6th edn.New York:Wiley-Liss,2002:199-202.
[7] HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[8] MUSCHEN M,WARSKULAT U,BECKMANN M W.Defining CD95 as a tumor suppressor gene[J].J Mol Med,2000,78(6):312-325.
[9] PERABO F G,MATTES R H,WIRGER A,et al.Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo[J].Urol Oncol,2001,6(4):163-169.
[10] MIZUTANI Y,YOSHIDA O,UKIMURA O,et al.Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer[J].Cancer Biother Radiopharm,2002,17(5):563-567.
[11] MIZUTANI Y,YOSHIDA O,BONAVIDA B.Prognostic significance of soluble Fas in the serum of patients with bladder cancer[J].J Urol,1998,160(2):571-576.
[12] SAROSDY M F,SCHELLHAMMER P,BOKINSKY G,et al.Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer[J].J Urol,2002,168(5):1950-1954.
[13] BABJUK M,OOSTERLINCK W,SYLVESTER R,et al.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder,the 2011 update[J].Actas Urol Esp,2012,36(7):389-402.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录